By Fineline Cube Jinling Pharmaceutical Co., Ltd. (SHE: 000919) announced that the marketing authorization application for its Ferric Carboxymaltose Injection has been accepted by China’s National Medical Products Administration (NMPA).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Application Type | Marketing authorization application acceptance |
| Product | Ferric Carboxymaltose Injection |
| Indication | Treatment of iron deficiency anemia |
| Acceptance Date | 3 Aug 2026 |
| Next Steps | Formal NMPA review process (estimated 12-18 months) |
Drug Profile & Clinical Value
- Molecule: Third-generation intravenous iron agent
- Originator: Vifor Pharma Management Ltd. of Switzerland (brand name: Ferinject)
- Innovation: Clinically well-tolerated formulation providing rapid and effective treatment for iron deficiency anemia
- Target Population: Patients who respond poorly to oral iron supplements, cannot take oral iron, or require urgent iron replenishment
- Market Status: Currently only imported originator product available in China; Jinling Pharma positioned to become first generic manufacturer
Market Opportunity & Competitive Landscape
Iron deficiency anemia affects an estimated 200 million people in China, representing one of the most prevalent nutritional disorders in the country. The intravenous iron market is projected to reach $500 million annually by 2028, driven by increasing diagnosis rates and expanding treatment guidelines.
Jinling Pharmaceutical’s entry as the potential first generic manufacturer would significantly disrupt the current market dominated solely by the imported originator product, potentially improving accessibility and reducing treatment costs for Chinese patients.
Company Strategy & Manufacturing Capabilities
“This regulatory acceptance reflects our commitment to addressing unmet medical needs in hematology and nutrition,” said a Jinling Pharmaceutical spokesperson. “We believe our ferric carboxymaltose formulation offers significant advantages in terms of dosing convenience and patient tolerability.”
The company has invested significantly in its manufacturing capabilities for complex injectable products, with dedicated facilities compliant with China’s Good Manufacturing Practice (GMP) standards and international quality requirements.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory timelines, market opportunities, and commercial expectations for Ferric Carboxymaltose Injection. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech